Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
复制标题
抗表皮生长因子受体抗体在化学难治性转移性结直肠癌中的重新给药。
DOI：
10.21873/anticanres.12101
复制
发表时间：
2017
影响因子：
2
通讯作者：
T. Esaki
中科院分区：
文献类型：
--
作者：
Tatsuhiro Kajitani;A. Makiyama;S. Arita;H. Shimokawa;H. Oda;T. Shirakawa;E. Baba;T. Esaki
背景/目的
在疾病进展后重新给予抗表皮生长因子受体（EGFR）抗体治疗转移性结直肠癌（mCRC）仍有待确定。
患者和方法
前瞻性观察了既往抗EGFR抗体难治性mCRC患者再次给予抗EGFR抗体的情况。
结果
共入组了13例患者，中位年龄为60岁，东部肿瘤协作组（ECOG）体能状态评分为0或1。既往化疗的中位次数为3次（范围2-5次）。12名患者既往接受过抗EGFR抗体联合细胞毒性药物治疗。抗EGFR抗体再给药方案为西妥昔单抗/帕尼单抗+卡培他滨/S-1（7例患者）、帕尼单抗+FOLFOX（3例患者）、西妥昔单抗+伊立替康（2例患者）和帕尼单抗单药治疗（1例患者）。7例患者在再次给药后病情稳定，6例患者病情进展。再次给药后的中位总生存期（OS）为228天，中位PFS为102天。抗EGFR治疗间隔超过90天的患者比间隔短于90天的患者表现出更有利的生存期。观察到治疗之间抗EGFR抗体的转换有助于生存。
结论
抗EGFR抗体再给药可在mCRC患者中显示出适度的生存获益，治疗间隔时间和抗体转换是重要的促成因素。
BACKGROUND/AIM
Readministration of anti-epidermal growth factor receptor (EGFR) antibody for metastatic colorectal cancer (mCRC) after disease progression remains to be determined.
PATIENTS AND METHODS
Readministration of anti-EGFR antibody in mCRC patients previously refractory to anti-EGFR antibody was prospectively observed.
RESULTS
A total of thirteen patients with a median age of 60-years old and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, were enrolled. The median number of previous chemotherapies was 3 (range 2-5). Prior anti-EGFR antibody in combination with cytotoxic drugs was administered in 12 patients. Anti-EGFR antibody readministration regimens were cetuximab/panitumumab plus capecitabine/S-1 (seven patients), panitumumab plus FOLFOX (three patients), cetuximab plus irinotecan (two patients), and panitumumab monotherapy (one patient). Seven patients showed stable disease following readministration and six patients showed progressive disease. The median overall survival (OS) following readministration was 228 days and the median PFS was 102 days. Patients with intervals longer than 90 days between anti-EGFR therapies exhibited more favorable survival than those with intervals shorter than 90 days. Switching of anti-EGFR antibody between treatments was observed to contribute survival.
CONCLUSION
Anti-EGFR antibody readministration could show a modest survival benefit in mCRC patients, with the length of therapy interval and switching of antibody being important contributory factors.
影响因子：
28.2
作者：
Bardelli A;Corso S;Bertotti A;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S
通讯作者：
Siena S
影响因子：
50.5
作者：
Morelli, M. P.;Overman, M. J.;Kopetz, S.
通讯作者：
Kopetz, S.